List of Studies ( Metabolite:GalCer 18:2;O2/20:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004162 | AN006907 | Targeted Lipid Profiling of Mouse Brains with GBA1 E326K Loss-of-Function | Brain | Mouse | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004162 | AN006907 | Targeted Lipid Profiling of Mouse Brains with GBA1 E326K Loss-of-Function | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006718 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006718 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
